Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kanzhun (BZ) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Kanzhun (BZ) over the last 6 years, with Q3 2025 value amounting to $4.7 billion.

  • Kanzhun's Cash & Equivalents rose 3529.83% to $4.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 billion, marking a year-over-year increase of 3529.83%. This contributed to the annual value of $2.8 billion for FY2024, which is 7112.17% down from last year.
  • Kanzhun's Cash & Equivalents amounted to $4.7 billion in Q3 2025, which was up 3529.83% from $436.8 million recorded in Q2 2025.
  • Kanzhun's Cash & Equivalents' 5-year high stood at $12.2 billion during Q3 2022, with a 5-year trough of $343.5 million in Q4 2023.
  • For the 5-year period, Kanzhun's Cash & Equivalents averaged around $2.6 billion, with its median value being $1.7 billion (2021).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 278602.94% in 2021, then plummeted by 9606.04% in 2024.
  • Kanzhun's Cash & Equivalents (Quarter) stood at $1.8 billion in 2021, then decreased by 22.71% to $1.4 billion in 2022, then plummeted by 74.95% to $343.5 million in 2023, then increased by 3.48% to $355.4 million in 2024, then skyrocketed by 1221.8% to $4.7 billion in 2025.
  • Its Cash & Equivalents was $4.7 billion in Q3 2025, compared to $436.8 million in Q2 2025 and $384.5 million in Q1 2025.